Prostate cancer is a malignant disease in which prostate cells acquire the ability to grow abnormally, invade surrounding tissue and, in some cancers, spread to lymph nodes, bone or other organs. More than 95% of primary prostate cancers are adenocarcinomas, meaning they arise from the gland-forming epithelial cells responsible for producing prostate fluid. Prostate cancer is not one uniform disease: some tumors remain small and slow-growing for years, while others contain higher-grade cellular patterns that are more likely to invade, recur or metastasize.
Prostate adenocarcinoma is a malignant gland-forming epithelial tumor originating in the prostate. “Malignant” means the cells are no longer simply enlarging in place: they have acquired biological features that allow abnormal proliferation, invasion through normal tissue boundaries and, in some cancers, metastatic spread. That separates prostate cancer from benign prostate enlargement, inflammation and infection.
01What Is Prostate Cancer?
The cancer begins in prostate tissue
The prostate is a gland of the male reproductive system located below the bladder and in front of the rectum. It surrounds the first part of the urethra and contributes fluid to semen.
Prostate cancer begins when cells within this gland acquire molecular changes that disrupt the normal controls over:
- cell division;
- cell survival;
- DNA repair;
- interaction with surrounding tissue;
- and normal glandular organization.
The resulting population of abnormal cells can form a malignant tumor.
Why is it called adenocarcinoma?
An adenocarcinoma is a cancer arising from glandular epithelial tissue.
That description fits the overwhelming majority of prostate cancers because normal prostate tissue is largely composed of glands that make and release prostate secretions.
According to the National Cancer Institute, more than 95% of primary prostate cancers are adenocarcinomas.
Are there other types of prostate cancer?
Yes, but they are much less common.
Rare cancers arising in or involving the prostate include:
- small-cell neuroendocrine carcinoma;
- other neuroendocrine carcinomas;
- urothelial carcinoma;
- and sarcomas.
These cancers can behave differently from conventional prostate adenocarcinoma and may require different treatment strategies.
Therefore, the word “prostate cancer” usually refers to adenocarcinoma unless pathology identifies another tumor type.
Where in the prostate does adenocarcinoma usually arise?
Many prostate adenocarcinomas arise in the peripheral zone, which lies toward the outer posterior portion of the gland.
This helps explain two clinical observations:
- a tumor can sometimes be palpable during digital rectal examination;
- and a meaningful cancer can exist without initially compressing the urethra enough to cause urinary symptoms.
Cancer can also arise in other prostate regions, including the transition zone.
Is prostate cancer always one single tumor?
No.
Prostate adenocarcinoma is frequently multifocal, meaning separate tumor foci can exist within the same prostate.
It can also be biologically heterogeneous. Different tumor areas may contain different:
- Gleason patterns;
- molecular changes;
- growth characteristics;
- and degrees of clinical importance.
This heterogeneity is one reason biopsy sampling and MRI interpretation require careful clinical context.
An enlarged prostate is not automatically cancer, a painful prostate is not automatically cancer, and an elevated PSA is not automatically cancer. Prostate cancer is a specific malignant tissue diagnosis whose biological behavior is then characterized by grade, stage and other risk features.
02How Does Prostate Adenocarcinoma Begin and Grow?
Cancer develops through accumulated biological changes
Normal prostate epithelial cells follow tightly regulated instructions controlling when to divide, repair damaged DNA and die when they are no longer needed.
Cancer develops when a population of cells accumulates molecular changes that progressively weaken those controls.
Depending on the tumor, these changes can affect:
- androgen signaling;
- DNA repair pathways;
- cell-cycle control;
- tumor suppressor genes;
- chromosome structure;
- and communication between tumor cells and surrounding tissue.
No single mutation explains every prostate cancer.
Does one abnormal prostate cell immediately become an invasive cancer?
No.
Cancer development is generally a multistep biological process.
Some prostates contain precursor-like abnormalities such as high-grade prostatic intraepithelial neoplasia (HGPIN), where epithelial cells look abnormal but remain within existing glandular structures.
HGPIN is associated with prostate adenocarcinoma and may represent a precursor pathway in some cancers, but it does not mean invasive cancer is inevitable.
What makes invasive cancer different?
A defining malignant change is the ability to grow beyond normal tissue boundaries.
In benign glandular tissue, epithelial cells remain organized within gland structures supported by a normal basal-cell layer and surrounding tissue framework.
In prostate adenocarcinoma, malignant epithelial cells develop an infiltrative pattern and extend into the surrounding prostate stroma.
That ability to invade separates a true carcinoma from a non-invasive cellular abnormality.
Why can prostate cancer grow slowly in one person and quickly in another?
Because “prostate cancer” describes a family of biologically different tumors rather than one identical clone.
Tumors can differ in:
- their underlying genomic alterations;
- how dependent they are on androgen signaling;
- how rapidly cells divide;
- how effectively they repair DNA;
- whether aggressive patterns such as cribriform or intraductal disease are present;
- and whether they have already acquired the ability to invade surrounding structures.
What role do androgens play?
Normal prostate cells respond to androgens such as testosterone and dihydrotestosterone. Many prostate adenocarcinoma cells retain this androgen dependence.
Androgen receptor signaling can promote survival and growth in prostate cancer, which is why reducing androgen signaling is an important treatment strategy in several disease stages.
However, androgen dependence can change during disease evolution. Advanced cancer can eventually grow despite very low circulating testosterone, a state known as castration-resistant prostate cancer.
Does testosterone simply “cause” prostate cancer?
That is too simplistic.
Androgens are important biological signals for prostate tissue, but prostate carcinogenesis involves complex interactions among:
- aging;
- inherited susceptibility;
- acquired genomic changes;
- cellular signaling;
- the surrounding tissue environment;
- and other biological influences.
The existence of androgen-sensitive cancer does not mean a man’s natural testosterone level by itself explains why the cancer developed.
Why does grade matter?
As prostate cancer loses normal glandular organization, its microscopic architecture becomes increasingly abnormal.
Pathologists capture that biological information using Gleason patterns and Grade Groups.
Lower-grade adenocarcinoma retains more recognizable gland formation. Higher-grade cancers show increasingly fused, poorly formed or solid growth patterns.
That microscopic architecture helps estimate how likely the tumor is to behave aggressively, but grade is not the same as anatomical stage.
The phrase “prostate cancer” establishes malignancy, but it does not tell us whether immediate treatment is needed. That decision requires additional information about Grade Group, PSA, tumor extent, stage, patient health and life expectancy. Some low-risk cancers can be monitored safely with structured active surveillance.
03How Does Prostate Cancer Grow Beyond the Prostate and Spread?
Local invasion happens before distant metastasis in many cancers
A prostate tumor begins within the gland.
As an invasive cancer enlarges, it may extend through prostate tissue and eventually involve structures immediately outside the gland.
Possible sites of local extension include:
- tissue beyond the prostate capsule;
- seminal vesicles;
- the bladder neck in more advanced local disease;
- and other nearby pelvic structures in extensive cancers.
What does extracapsular or extraprostatic extension mean?
It means cancer has grown beyond the normal boundary of the prostate into surrounding tissue.
This is an important staging feature because a cancer confined within the gland and a cancer extending beyond it have different anatomical extents and may require different treatment planning.
How does prostate cancer reach lymph nodes?
Cancer cells can enter lymphatic vessels and travel to regional pelvic lymph nodes.
Regional nodal spread is represented by the N component of TNM staging.
The presence or absence of lymph-node involvement affects:
- stage;
- prognostic assessment;
- radiation planning in selected patients;
- and systemic-treatment decisions.
How does prostate cancer metastasize to distant organs?
Cancer cells can enter blood vessels or lymphatic channels, survive transport through the body and establish new tumor deposits in distant tissues.
The National Cancer Institute defines this process as metastasis.
Importantly, a metastatic tumor retains the biological identity of the original cancer.
If prostate cancer spreads to bone, the cells in the bone lesion are prostate-cancer cells—not primary bone-cancer cells.
Why is bone an important metastatic site?
Bone is one of the characteristic sites of distant prostate-cancer spread.
Prostate-cancer bone metastases often stimulate abnormal bone formation and can appear osteoblastic or sclerotic on imaging.
Advanced skeletal disease can cause:
- bone pain;
- fracture risk;
- spinal instability;
- bone-marrow effects;
- and, when vertebral disease compresses neural structures, spinal cord or cauda equina emergencies.
Can prostate cancer spread elsewhere?
Yes.
Distant disease can also involve:
- non-regional lymph nodes;
- lung;
- liver;
- and other organs.
The exact pattern varies between patients and often reflects both disease biology and how advanced the cancer has become.
Does every prostate cancer eventually spread?
No.
Many prostate cancers remain organ-confined for long periods, and some low-risk cancers may never threaten a man’s health during his lifetime.
The likelihood of progression depends on features such as:
- Grade Group;
- PSA level and PSA density;
- tumor volume;
- local stage;
- molecular features in selected cases;
- and changes observed over time.
What is the difference between grade and stage?
Grade describes how abnormal and aggressive the cancer looks microscopically.
Stage describes anatomical extent.
For example, a cancer may be:
- high grade but still anatomically confined to the prostate;
- or lower grade but more extensive than originally expected.
These variables are interpreted together when estimating prognosis and selecting treatment.
Metastatic disease is not the definition of prostate cancer. A prostate tumor becomes cancer when malignant glandular cells invade tissue. It does not need to have reached a lymph node or bone before it is considered cancer. Metastasis describes a later anatomical capability present in some—not all—prostate cancers.
04What Does a Prostate Cancer Diagnosis Mean—and What Does It Not Mean?
A prostate-cancer diagnosis does not automatically mean advanced disease
Cancer can be diagnosed while it is:
- small;
- localized entirely within the prostate;
- low grade;
- and unlikely to cause harm in the near term.
At the other end of the spectrum, cancer can be high grade, locally invasive or metastatic.
The diagnosis therefore establishes what the tissue is, but additional information establishes how clinically threatening that cancer is.
A high PSA is not the same as a cancer diagnosis
PSA is produced by prostate tissue rather than specifically by prostate-cancer cells.
PSA can rise because of:
- prostate cancer;
- benign prostate enlargement;
- prostatitis;
- urinary retention;
- and some recent prostate or urinary procedures.
For the biomarker itself, see the PSA Testing hub.
The dedicated guide High PSA Without Cancer explains why an elevated result cannot be interpreted as malignancy by itself.
Prostatitis is not prostate cancer
Prostatitis describes several infectious, inflammatory and chronic-pain syndromes involving the prostate region.
Acute bacterial prostatitis can:
- cause fever;
- cause marked pelvic pain;
- produce urinary symptoms;
- and temporarily elevate PSA.
Those features do not transform inflammation into cancer.
The distinction between the two diseases is covered in Prostatitis vs Prostate Cancer.
Benign prostate enlargement is not prostate cancer
Benign prostatic hyperplasia is nonmalignant proliferation of prostate stromal and glandular tissue.
It can contribute to prostate enlargement and urinary obstruction, but benign cells do not acquire the invasive and metastatic behavior that defines malignancy.
A man can have:
- BPH without cancer;
- cancer without clinically important BPH;
- or both conditions at the same time.
Does an abnormal MRI prove cancer?
No.
Prostate MRI estimates the probability that a suspicious region may contain clinically significant cancer.
Inflammation and some benign changes can mimic cancer on MRI, while some cancers remain difficult to see.
This is why MRI is integrated with:
- PSA;
- PSA density;
- clinical risk;
- and biopsy decisions.
The relationship between these tests is introduced in the Prostate Cancer hub.
What usually confirms the diagnosis?
In the standard diagnostic pathway, prostate cancer is confirmed by histopathological examination of tissue obtained at biopsy or, less commonly, tissue obtained during another prostate procedure.
The pathologist identifies:
- the histological cancer type;
- Gleason growth patterns;
- Grade Group;
- the amount of sampled tissue involved;
- and selected additional pathological features.
Does finding cancer mean treatment must begin immediately?
No.
The next decision depends on the cancer’s risk.
Some patients with favorable localized disease may be candidates for structured active surveillance. Other patients have features that favor definitive local treatment or systemic therapy.
No one treatment is universally preferred for every prostate cancer.
What information matters after cancer is confirmed?
Once pathology confirms prostate cancer, clinicians still need to determine:
- histological type;
- Gleason score and Grade Group;
- PSA;
- amount of cancer sampled;
- local tumor extent;
- whether lymph nodes are involved;
- whether distant metastases are present when staging is indicated;
- patient age and overall health;
- and expected benefits and harms of available management strategies.
These attributes turn the broad diagnosis “prostate cancer” into an individual clinical risk profile.
Why can two men with prostate cancer need very different care?
Consider two simplified examples.
One patient might have a small Grade Group 1 cancer confined to the prostate with favorable PSA features. Another might have Grade Group 5 disease with seminal-vesicle invasion and distant bone metastases.
Both have prostate adenocarcinoma, but their:
- risk;
- prognosis;
- treatment goals;
- and appropriate management
are fundamentally different.
Clinical bottom line: prostate cancer is defined by malignant prostate tissue—not by urinary symptoms, PSA level, prostate size or MRI appearance alone. Most cancers are adenocarcinomas. The diagnosis becomes clinically meaningful only after the cancer’s grade, anatomical extent, PSA context and overall risk are established.
→Prostate Cancer Terms That Are Easy to Confuse
| Term | What it actually means | What it does not automatically mean |
|---|---|---|
| Prostate cancer | Malignant tumor arising in prostate tissue, usually adenocarcinoma. | Metastatic or incurable disease. |
| Adenocarcinoma | Malignant epithelial cancer showing glandular differentiation. | A separate disease from prostate cancer in the usual case; it is the dominant histological type. |
| Tumor | An abnormal tissue growth or mass. | Every tumor is malignant; benign tumors also exist. |
| Malignant | Capable of tissue invasion and potentially metastatic spread. | That distant metastasis has already occurred. |
| Localized prostate cancer | Cancer confined to the prostate in the relevant staging context. | That the cancer is biologically harmless. |
| Locally advanced cancer | Cancer extending beyond the prostate into nearby structures and/or regional context depending on classification. | Automatically widespread distant metastasis. |
| Metastatic prostate cancer | Prostate-cancer cells established at distant sites. | A new cancer arising from the metastatic organ. |
| Gleason pattern | Microscopic architectural pattern of prostate adenocarcinoma. | An anatomical stage. |
| Grade Group | A 1–5 pathology system summarizing microscopic aggressiveness. | The physical amount or location of cancer by itself. |
| Stage | Extent of the tumor locally, in lymph nodes and at distant sites. | Microscopic grade. |
| High PSA | Elevated blood concentration of prostate-specific antigen. | A confirmed prostate-cancer diagnosis. |
| PI-RADS lesion | An MRI finding assigned a level of suspicion for clinically significant cancer. | Histological proof of cancer. |
| BPH | Benign stromal and glandular prostate hyperplasia. | A precancerous form of prostate adenocarcinoma. |
| Prostatitis | Infectious, inflammatory or chronic pelvic-pain conditions involving the prostate region. | Prostate cancer. |
?Common Questions About What Prostate Cancer Is
| Question | Practical answer |
|---|---|
| What exactly is prostate cancer? | A malignant tumor arising from prostate cells, most commonly gland-forming epithelial cells. |
| What is prostate adenocarcinoma? | The most common type of prostate cancer, arising from glandular epithelial cells of the prostate. |
| How common is adenocarcinoma among prostate cancers? | NCI pathology information states that more than 95% of primary prostate cancers are adenocarcinomas. |
| Are there other prostate cancers? | Yes. Rare types include small-cell neuroendocrine carcinoma, other neuroendocrine tumors, urothelial carcinoma and sarcoma. |
| Is prostate cancer always aggressive? | No. Biological behavior ranges from slow-growing localized cancer to aggressive metastatic disease. |
| Can prostate cancer stay inside the prostate? | Yes. Many cancers are diagnosed while still localized. |
| Does prostate cancer always cause urinary symptoms? | No. Early prostate cancer can exist without noticeable urinary symptoms. |
| Does an enlarged prostate mean cancer? | No. Benign enlargement is common and biologically different from malignant prostate cancer. |
| Can BPH turn into prostate cancer? | BPH is not considered a premalignant form of prostate adenocarcinoma. The conditions can coexist. |
| Is prostatitis a form of prostate cancer? | No. Prostatitis describes infection, inflammation or chronic pelvic-pain syndromes. |
| Can prostatitis raise PSA? | Yes. Active inflammation can raise PSA without cancer being present. |
| Does high PSA mean cancer cells are present? | No. PSA is prostate-specific but not cancer-specific. |
| Does a prostate MRI diagnose cancer? | MRI estimates suspicion and maps lesions, but pathology usually confirms the diagnosis. |
| What test confirms prostate cancer? | Histopathological examination of prostate tissue, usually obtained by biopsy. |
| What does malignant mean? | It means the abnormal cells have cancerous biological behavior including tissue invasion and potential for metastatic spread. |
| Does malignant mean metastatic? | No. A cancer can be malignant while still completely localized to the prostate. |
| What does invasive mean? | Cancer cells have grown beyond the normal gland structures into surrounding tissue. |
| What is metastasis? | The spread of cancer cells from the primary tumor to another part of the body where they establish new tumor deposits. |
| If prostate cancer reaches bone, is it bone cancer? | No. It remains metastatic prostate cancer because the metastatic cells originated from the prostate. |
| Where does prostate cancer commonly spread? | Important sites include lymph nodes and bone; advanced disease can also involve other organs. |
| What is Grade Group? | A pathology classification from 1 to 5 based on Gleason patterns and the microscopic aggressiveness of prostate cancer. |
| Is Grade Group the same as stage? | No. Grade describes microscopic biology; stage describes anatomical extent. |
| Does every prostate cancer need treatment immediately? | No. Some favorable localized cancers can be managed with structured active surveillance. |
| Can two prostate cancers behave completely differently? | Yes. Tumor grade, molecular biology, volume and anatomical stage vary substantially between patients. |
ΣSummary
- Prostate cancer is a malignant tumor arising from cells within prostate tissue.
- More than 95% of primary prostate cancers are adenocarcinomas.
- Adenocarcinoma arises from gland-forming epithelial cells.
- The prostate normally produces fluid that contributes to semen.
- Prostate cancer is not one biologically uniform disease.
- Some prostate cancers grow slowly and remain localized for many years.
- Other prostate cancers contain aggressive biological features and can invade or metastasize.
- Rare non-adenocarcinoma prostate cancers include neuroendocrine carcinoma, urothelial carcinoma and sarcoma.
- Prostate adenocarcinoma frequently arises in the peripheral zone.
- Many prostate cancers are multifocal.
- Different tumor areas within the same prostate can show different biological characteristics.
- Cancer develops through accumulated changes in normal cellular growth control.
- No single genetic alteration explains every prostate adenocarcinoma.
- High-grade prostatic intraepithelial neoplasia can be associated with prostate cancer but does not guarantee invasive cancer will develop.
- Invasive adenocarcinoma grows beyond normal glandular boundaries into surrounding tissue.
- Invasion is a defining malignant property.
- Metastasis is not required before a prostate tumor is called cancer.
- Androgen receptor signaling plays an important role in normal prostate biology and many prostate cancers.
- Natural testosterone level alone does not explain prostate carcinogenesis.
- Prostate cancers differ in their dependence on androgen signaling.
- Grade describes microscopic architectural aggressiveness.
- Stage describes anatomical extent.
- Grade and stage are not interchangeable.
- Local progression can involve tissue outside the prostate and the seminal vesicles.
- Prostate cancer can spread through lymphatic vessels to regional nodes.
- Cancer cells can also enter the bloodstream and establish distant metastases.
- Bone is an important metastatic site in advanced prostate cancer.
- A bone metastasis from prostate cancer remains biologically prostate cancer.
- Prostate cancer can also metastasize to distant lymph nodes, lung, liver and other sites.
- Not every prostate cancer eventually metastasizes.
- Many lower-risk cancers remain localized and may never cause clinically important disease during a patient’s lifetime.
- Prostate cancer can exist without urinary symptoms.
- Urinary symptoms are not specific for prostate cancer.
- BPH is a benign process and is not the same disease as prostate adenocarcinoma.
- BPH and prostate cancer can coexist in the same prostate.
- Prostatitis is not prostate cancer.
- Inflammation and infection can produce symptoms that overlap with prostate cancer evaluation.
- Prostatitis can raise PSA without malignancy.
- PSA is prostate-specific but not cancer-specific.
- A high PSA does not confirm cancer.
- An abnormal MRI does not prove cancer.
- A negative MRI does not completely exclude clinically significant cancer.
- Biopsy provides prostate tissue for histological diagnosis.
- Pathology establishes whether adenocarcinoma is present and assigns microscopic grade.
- A prostate-cancer diagnosis does not automatically mean advanced disease.
- A cancer can be malignant while still localized entirely within the prostate.
- Some favorable localized prostate cancers can be managed with active surveillance.
- Other cancers require local or systemic treatment according to risk and stage.
- No prostate-cancer treatment is universally preferred for every patient.
- The clinically important sequence is diagnosis → grade → stage → individual risk → management.
Clinical bottom line: prostate cancer is defined by malignant prostate tissue, most often adenocarcinoma. What happens next depends on biology and extent. The words “prostate cancer” alone do not tell us whether the disease is slow-growing or aggressive, localized or metastatic, suitable for surveillance or in need of treatment.
Medical disclaimer: This article provides general medical education about prostate cancer biology. PSA results, MRI findings and symptoms cannot independently diagnose prostate cancer. Tissue diagnosis, Grade Group, stage, health status and individual risk require interpretation by qualified clinicians. New severe neurological weakness, loss of bladder or bowel control, or rapidly progressive symptoms in a person with known advanced prostate cancer warrant prompt medical assessment.
For the complete route from risk and PSA through MRI, biopsy, grading, staging, treatment and follow-up, return to the Prostate Cancer hub. For the biomarker used throughout detection and follow-up, see PSA Testing. The next guide examines prostate-cancer symptoms, why early disease may be silent, and which urinary, skeletal or systemic symptoms require a different level of concern.
Evidence Sources
- National Cancer Institute — Prostate Cancer Treatment, Health Professional Version: Pathology, Adenocarcinoma and Disease Biology.
- National Cancer Institute — Prostate Cancer Treatment, Patient Version: Definition, Diagnosis, Stage and Metastatic Spread.
- National Cancer Institute — What Is Cancer?: Malignant Growth, Invasion and Metastasis.
- National Cancer Institute Dictionary of Cancer Terms — Adenocarcinoma.
- European Association of Urology — Prostate Cancer Classification and Staging Systems: TNM, Grade and Risk Classification.
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: PSA, MRI, Biopsy and Staging.
- American Cancer Society — What Is Prostate Cancer?: Adenocarcinoma and Rare Prostate Cancer Types.
